Biodexa Pharmaceuticals (BDRX) Finished Goods (2015 - 2017)

Biodexa Pharmaceuticals (BDRX) has 3 years of Finished Goods data on file, last reported at $1.2 million in Q4 2017.

• For the quarter ending Q4 2017, Finished Goods rose 23.0% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2017 stood at $1.2 million (up 23.0% YoY), and the FY2017 full-year result was $1.2 million, up 9.37% from the prior year.
• Finished Goods improved to $1.2 million in Q4 2017, from $1.0 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $1.2 million in Q4 2017 to a low of $347505.3 in Q4 2015.
• A 3-year average of $870850.2 and a median of $1.0 million in 2016 frame the typical range for Finished Goods.
• Across the five-year window, Finished Goods soared 192.29% in 2016 and increased 23.0% in 2017, its largest moves.
• Tracing BDRX's Finished Goods over 3 years: stood at $347505.3 in 2015, then soared by 192.29% to $1.0 million in 2016, then rose by 23.0% to $1.2 million in 2017.
• Business Quant data shows BDRX's Finished Goods at $1.2 million in Q4 2017, $1.0 million in Q4 2016, and $347505.3 in Q4 2015.